DE60001229T2 - Triarylimidazole - Google Patents
TriarylimidazoleInfo
- Publication number
- DE60001229T2 DE60001229T2 DE60001229T DE60001229T DE60001229T2 DE 60001229 T2 DE60001229 T2 DE 60001229T2 DE 60001229 T DE60001229 T DE 60001229T DE 60001229 T DE60001229 T DE 60001229T DE 60001229 T2 DE60001229 T2 DE 60001229T2
- Authority
- DE
- Germany
- Prior art keywords
- triarylimidazoles
- andone
- 6alkyl
- chr
- pharmaceuticals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12868799P | 1999-04-09 | 1999-04-09 | |
PCT/US2000/009147 WO2000061576A1 (en) | 1999-04-09 | 2000-04-06 | Triarylimidazoles |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60001229D1 DE60001229D1 (de) | 2003-02-20 |
DE60001229T2 true DE60001229T2 (de) | 2003-10-30 |
Family
ID=22436501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60001229T Expired - Fee Related DE60001229T2 (de) | 1999-04-09 | 2000-04-06 | Triarylimidazole |
Country Status (9)
Country | Link |
---|---|
US (1) | US6465493B1 (de) |
EP (1) | EP1169317B1 (de) |
JP (1) | JP2002541253A (de) |
AT (1) | ATE231143T1 (de) |
AU (1) | AU4798000A (de) |
CO (1) | CO5031285A1 (de) |
DE (1) | DE60001229T2 (de) |
ES (1) | ES2187473T3 (de) |
WO (1) | WO2000061576A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
WO2001089556A1 (en) * | 2000-05-19 | 2001-11-29 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Inhibition of smad3 to prevent fibrosis and improve wound healing |
AU2002225730A1 (en) * | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
GB0100762D0 (en) * | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
GB0102665D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
AU2002339268B2 (en) | 2001-05-24 | 2007-05-31 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
AU2003256297A1 (en) | 2002-08-09 | 2004-02-25 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
WO2004026307A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
CA2496295C (en) | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
OA12925A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |
AP2005003264A0 (en) * | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGD) inhibitors. |
EP1542994B1 (de) | 2002-09-18 | 2009-04-29 | Pfizer Products Inc. | Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf) |
EP1589960A4 (de) * | 2002-12-19 | 2008-09-10 | Scios Inc | Behandlung von adipositas und verwandten erkrankungen mit tgf-beta inhibitoren |
US7361669B2 (en) | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
JPWO2004108160A1 (ja) * | 2003-06-05 | 2006-07-27 | 日本新薬株式会社 | 骨形成促進増強剤及びそのスクリーニング方法 |
AU2004274326B2 (en) | 2003-09-17 | 2011-11-17 | Sumitomo Chemical Company, Limited | Cinnamoyl derivatives and use thereof |
JP2006104061A (ja) * | 2003-09-17 | 2006-04-20 | Sumitomo Chemical Co Ltd | シンナモイル化合物含有i型コラーゲン遺伝子転写抑制組成物。 |
JP4815773B2 (ja) * | 2003-09-17 | 2011-11-16 | 住友化学株式会社 | シンナモイル化合物及びその用途 |
US7678810B2 (en) | 2004-03-05 | 2010-03-16 | Taisho Pharmaceutical Co., Ltd | Thiazole derivative |
KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Alk5 및/또는 alk4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
US20080319012A1 (en) | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
US7429604B2 (en) * | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
EP1771171A1 (de) * | 2004-07-29 | 2007-04-11 | Schering-Plough Ltd. | Verwendung von alk-5-hemmern zur modulation bzw. hemmung der myostatinaktivität zur verstärkung von magergewebe bei tieren |
CN101263121A (zh) | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
WO2008066626A2 (en) | 2006-10-25 | 2008-06-05 | The Rockefeller University | METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR |
WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
WO2008094556A2 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
EP2152093A4 (de) * | 2007-05-04 | 2011-05-25 | Jana Pickova | Verbundfutter für aquakulturen |
ES2617957T3 (es) | 2007-08-03 | 2017-06-20 | Summit (Oxford) Limited | Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
AU2012203026B2 (en) * | 2008-03-21 | 2014-06-12 | Novartis Ag | Novel heterocyclic compounds and uses thereof |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
WO2012167261A2 (en) * | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
PT2731949T (pt) | 2011-07-13 | 2018-06-15 | Tiumbio Co Ltd | Imidazóis substituídos com 2-piridilo como inibidores de alk5 e/ou alk4 |
EP2855665B8 (de) | 2012-05-30 | 2019-09-25 | Cornell University | Erzeugung von funktionellen und beständigen endothelzellen aus zellen aus menschlicher amniotischer flüssigkeit |
RS60318B1 (sr) | 2012-08-01 | 2020-07-31 | Ikaika Therapeutics Llc | Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela |
CA2901747A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
EP3888640A1 (de) | 2013-06-05 | 2021-10-06 | AgeX Therapeutics, Inc. | Zusammensetzungen und verfahren zur induzierten geweberegeneration in säugerspezies |
AU2015204566A1 (en) | 2014-01-09 | 2016-08-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
JP6705115B2 (ja) | 2014-04-18 | 2020-06-03 | 京都府公立大学法人 | 骨芽細胞の調製方法及び骨芽細胞誘導剤 |
WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
US11541149B2 (en) | 2015-12-11 | 2023-01-03 | Research Institute At Nationwide Children's Hospital | Systems and methods for optimized patient specific tissue engineering vascular grafts |
EP3897689A1 (de) | 2018-12-21 | 2021-10-27 | Northwestern University | Verwendung von annexinen zur vorbeugung und behandlung von muskelmembranverletzungen |
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
CN115052663A (zh) | 2020-01-08 | 2022-09-13 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
AU2021307560A1 (en) | 2020-07-15 | 2023-02-23 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine amino derivatives as ALK5 inhibitors |
CA3184990A1 (en) | 2020-07-15 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB138101A (de) | ||||
CH561716A5 (de) * | 1971-05-10 | 1975-05-15 | Ciba Geigy Ag | |
US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
EP1306377A3 (de) * | 1993-11-08 | 2003-05-07 | Smithkline Beecham Corporation | Pyridyl-Oxazole und ihre Verwendung als Cytokine-Inhibitoren |
US5776954A (en) | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
WO1998022109A1 (en) * | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
JPH11180958A (ja) * | 1997-12-24 | 1999-07-06 | Yamanouchi Pharmaceut Co Ltd | 新規アミン誘導体 |
-
2000
- 2000-04-06 ES ES00930101T patent/ES2187473T3/es not_active Expired - Lifetime
- 2000-04-06 AT AT00930101T patent/ATE231143T1/de not_active IP Right Cessation
- 2000-04-06 US US09/958,639 patent/US6465493B1/en not_active Expired - Fee Related
- 2000-04-06 AU AU47980/00A patent/AU4798000A/en not_active Abandoned
- 2000-04-06 EP EP00930101A patent/EP1169317B1/de not_active Expired - Lifetime
- 2000-04-06 WO PCT/US2000/009147 patent/WO2000061576A1/en active IP Right Grant
- 2000-04-06 DE DE60001229T patent/DE60001229T2/de not_active Expired - Fee Related
- 2000-04-06 JP JP2000610849A patent/JP2002541253A/ja not_active Withdrawn
- 2000-04-10 CO CO00026001A patent/CO5031285A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000061576A1 (en) | 2000-10-19 |
EP1169317A1 (de) | 2002-01-09 |
AU4798000A (en) | 2000-11-14 |
EP1169317B1 (de) | 2003-01-15 |
ATE231143T1 (de) | 2003-02-15 |
DE60001229D1 (de) | 2003-02-20 |
US6465493B1 (en) | 2002-10-15 |
CO5031285A1 (es) | 2001-04-27 |
JP2002541253A (ja) | 2002-12-03 |
ES2187473T3 (es) | 2003-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60001229D1 (de) | Triarylimidazole | |
CO5280078A1 (es) | Compuestos | |
AP1614A (en) | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents. | |
MX9605128A (es) | Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
BG106586A (en) | Pyrazolopyramidines as therapeutic agents | |
MXPA03002911A (es) | Compuestos quimicos. | |
DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
AU2001266575A1 (en) | Chemical compounds | |
MXPA02012076A (es) | Compuestos quimicos. | |
GEP20053626B (en) | Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof | |
WO2002062767A1 (fr) | Nouveaux derives de quinazoline | |
PL341239A1 (en) | Dihydrobenzofuranes | |
TR200201128T2 (tr) | PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri. | |
AU2001263278A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
MXPA02004441A (es) | Derivados de isoxazol como inhibidores de la fosfodiesterasa. | |
ATE213241T1 (de) | Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase | |
ATE330958T1 (de) | Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate | |
HRP20010885B1 (en) | Ethanesulfonyl-piperidine derivatives | |
AU3565700A (en) | Antibacterial agents | |
NZ504614A (en) | Echinocandin derivatives and application as anti-fungal agents | |
SE9901901D0 (sv) | Compounds | |
TR200001122T2 (tr) | Farmasötikler olarak bifenil türevleri. | |
SE9603284D0 (sv) | New compounds | |
SE9802650D0 (sv) | Compounds | |
SI0937075T1 (en) | New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |